Treatment with dapagliflozin and empagliflozin reduces concentrations of N4-acetylcytidine in plasma, a biomarker associated with vascular damage.

PubMed 1970-01-01 added 2026-07-25

Gessner A, Kannenkeril D, Bosch A, Harazny JM, Fromm MF, Klinkhammer H, Staerk C, Mayr A, Schmieder RE, Maas R